InsidersTradesSigma
Follow the Cantourage Group SE share price and the full directors' dealings record of the company, a publicly traded company based in Germany. Shares trade on the DE market, under the supervision of BaFin. Operating in the Healthcare & Pharma sector, Cantourage Group SE has published 4 public disclosures. Market capitalisation: €69.9m. The latest transaction was reported on 8 June 2026 (Other). Among the most active insiders: Schetter, Philip. Every trade is accessible without an account.
4
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Cantourage Group SE Strong Buy (bullish), based on 3 analysts. Average price target: €10.50.
Fundamental score
Ranked 25,919 of 29,064 companies
22.8
score / 100
Value18
Quality28
FCF yld·
Earn yld-6.1%
EV/EBITDA·
ROE0.3%
Gross mgn31%
Net mgn-18%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 June 2026
Declarations4 total
Other financial instr. linked to share;debt instr.ISIN DE000A3DSV01BAFIN:40034424-72c746d29067
Other financial instr. linked to share;debt instr.ISIN DE000A3DSV01BAFIN:40034424-c1d594e97bc0
ShareISIN DE000A3DSV01BAFIN:40034424
ShareISIN DE000A3DSV01BAFIN:40034424-28696f5f2e54
4 of 4 declarations
关于 Cantourage Group SE
Cantourage Group SE是一家德国公司，专注于医用大麻，在德国Xetra/法兰克福（DAX/MDAX/SDAX）上市，股票代码为HIGH.DE。该公司成立于2019年，总部位于柏林，其业务围绕着一个欧洲医用大麻平台模式建立，涵盖为患者和医疗专业人员采购、加工、商业化和分销花卉及相关产品。其战略核心是提供符合欧洲各地医疗市场监管标准的精选菌株和产品。([stockanalysis.com](https://stockanalysis.com/quote/etr/HIGH/company/?utm_source=openai)) 在运营方面，Cantourage主要涉足医用大麻领域，历史上一直高度重视德国市场，同时也在向其他欧洲市场扩张，特别是英国和波兰。该公司还强调其在德国和葡萄牙的加工和供应链能力，表明其拥有跨境运营足迹。管理层已将集团定位为产品多元化和国际化，以减少对单一市场的依赖，并抓住欧洲不断发展的医用大麻框架带来的增长机会。([cantourage.com](https://www.cantourage.com/en/blog-posts/cantourage-achieves-new-revenue-record-eur-11-1-million-in-april-2025?utm_source=openai)) Cantourage是欧洲医用大麻领域中较为知名的上市公司之一。其价值主张结合了监管专业知识、产品组合、处方渠道以及服务不断增长的患者群体的能力。然而，竞争环境依然严峻，尤其是在德国，医用大麻花的价格压力可能会影响利润率。该公司表示正在将其产品组合转向利润率更高的优质产品，这突显了产品组合和定价在其财务状况中的重要性。([eqs-news.com](https://www.eqs-news.com/news/corporate/cantourage-group-se-publishes-preliminary-figures-for-2025-revenue-rises-to-eur-92-8-million/46257867-d503-47fd-ac34-736f7f5ff130_en?utm_source=openai)) 最近的里程碑包括2025年初步数据显示收入为92.8 million欧元，管理层强调持续增长和国际市场贡献的增加。Cantourage还在2025年4月报告了创纪录的月收入，并在2025年第一季度表现出强劲的交易势头。这些更新强化了公司快速增长的轨迹，同时也突显了德国市场的监管敏感性。对于投资者而言，Cantourage是一个具有巨大上行潜力的利基医疗保健敞口，但它仍然与医用大麻的法律、定价和市场结构发展密切相关。([eqs-news.com](https://www.eqs-news.com/news/corporate/cantourage-group-se-publishes-preliminary-figures-for-2025-revenue-rises-to-eur-92-8-million/46257867-d503-47fd-ac34-736f7f5ff130_en?utm_source=openai))
